Company profile
Greenwich LifeSciences, Inc.
Pipeline1 asset
- GLSI-100GP2 + GM-CSF / HER2/neu / peptide immunotherapy vaccine / OncologyPrevention of recurrence in HER2/neu-positive breast cancer after surgery and trastuzumab-based therapyPhase 3Ongoing; Fast Track designated; FLAMINGO-01United StatesEurope
Latest news12 items
All newsGreenwich LifeSciences Provides Update Regarding Form 10-K Filing
Interim Data • Phase 3
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
Presentation / Abstract • Phase 3
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
Presentation / Abstract • Phase 3
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
Presentation / Abstract • Phase 3